Are there patient characteristics associated with improvements or worsening in the placebo arm of COPD tlinical trials?

A. Anzueto, D. Tashkin, S. Kesten (San Antonio, TX, Los Angeles, CA, United States Of America; Biberach, Germany)

Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Session: Recent advances in the treatment and pathogenesis of pulmonary diseases II
Session type: E-Communication Session
Number: 4637
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Anzueto, D. Tashkin, S. Kesten (San Antonio, TX, Los Angeles, CA, United States Of America; Biberach, Germany). Are there patient characteristics associated with improvements or worsening in the placebo arm of COPD tlinical trials?. Eur Respir J 2008; 32: Suppl. 52, 4637

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials
Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019
Year: 2019



Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials
Source: Eur Respir J 2001; 18: Suppl. 33, 331s
Year: 2001

Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial>
Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections
Year: 2019




Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial
Source: Eur Respir J, 54 (5) 1802134; 10.1183/13993003.02134-2018
Year: 2019



Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Effect of tele healthcare on quality of life in patients with severe COPD: a randomized clinical trial
Source: International Congress 2017 – Best abstracts in physical activity and management of COPD
Year: 2017

A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis
Source: Annual Congress 2004 - Bronchiectasis
Year: 2004


QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015

A randomised clinical trial to assess the effect of active muscle stimulation on hospitalised patients with COPD exacerbations
Source: Annual Congress 2012 - The best posters on physical inactivity, muscle dysfunction and exercise intolerance
Year: 2012

Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Year: 2006

Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021


Improving morning activities in COPD patients with budesonide/formoterol: Assessment of data from two randomised trials using minimal important differences from a morning activities questionnaire
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019


Do COPD patients take timely measures in periods of symptom deterioration?
Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease
Year: 2009


Premature discontinuation of patients: a potential bias in COPD clinical trials
Source: Eur Respir J 2007; 30: 898-906
Year: 2007



The effect of aerobic and breathing exercises on clinical control and psychosocial status in patients with moderate and severe asthma: a RCT
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020